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This study aimed to develop a new biodegradable stent for peripheral artery disease (PAD) that could provide sufficient radial force
to maintain long-term patency and flexibility. All self-expandable hybrid biodegradable stents were designed by using a knitting
structure composed of poly-L-lactic acid (PLLA) and nitinol. Four different types of stents were implanted in 20 iliac arteries in
10 mini pigs as follows: a bare-metal stent (BMS) (group 1, 𝑛 = 5), a drug-free hybrid stent (group 2, 𝑛 = 5), a 50% (50 : 100,
w/w) paclitaxel (PTX)/poly-lactide-co-glycolic acid (PLGA; fast PTX-releasing form) hybrid stent (group 3, 𝑛 = 5), and a 30%
(30 : 100, w/w) PTX/PLGA (slow PTX-releasing form) hybrid stent (group 4, 𝑛 = 5). We performed follow-up angiography and
intravascular ultrasonography (IVUS) at 4 and 8 weeks. In a comparison of groups 1, 2, 3, and 4, less diameter stenosis was observed
in the angiographic analysis for group 4 at the 4-week follow-up (19.0% ± 12.7% versus 39.3% ± 18.1% versus 46.8% ± 38.0% versus
4.8% ± 4.2%, resp.; 𝑝 = 0.032). IVUS findings further suggested that the neointima of the patients in group 4 tended to be lesser
than those of the others. Our new biodegradable 30% PTX/PLGA (slow-releasing form) stent showed more favorable results for
patency than the other stent types.
1. Introduction
Biodegradable stents appear to be one of the most promising
tools in the field of endovascular intervention, offering
numerous potential benefits over permanent implants for the
treatment of cardiovascular disease. Percutaneous translumi-
nal angioplasty with primary stenting for peripheral artery
disease (PAD) can result in technical success and clinical ben-
efits [1]. Aside from improving flexibility, endovascular stent-
ing using nitinol metal stents may avoid problems such as
early elastic recoil, residual stenosis, and flow-limiting dissec-
tion after balloon angioplasty [2–4].
Despite the superiority of nitinol metal stents, several
major concerns emerged regarding their metallic compo-
nents, including stent fracture, late stent thrombosis, and late
restenosis. The superficial femoral artery is a harsh environ-
ment for a metallic stent, as mechanical forces such as
bending, torsion, compression, and elongation occur during
everyday activities [5]. Hence, the use of biodegradable
stents in PAD has previously been investigated [6, 7]. These
biodegradable stents have several limitations, including vas-
cular inflammation, lack of radial force for long-termpatency,
and acute recoiling after stent implantation. However, only
few clinical data are available regarding the use of biodegrad-
able stents for peripheral disease or experimental trials aimed
at developing new models of biodegradable stents. Thus, the
development of a new biodegradable stent for use in PAD is
necessitated. The primary aim of this study was to develop a
new biodegradable stent for PAD that could provide sufficient
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Figure 1: Stent design. (a) Conventional bare-metal stent. (b) Poly-L-lactic acid (PLLA) and nitinol knitting structure of the hybrid
biodegradable stent. (c) Self-expandable delivery system of the hybrid biodegradable stent.
radial force for the maintenance of patency, flexibility to
vessel geometry, and long-term patency by inhibiting intimal
hyperplasia.
2. Materials and Methods
2.1. Stent Design. The hybrid biodegradable stents were
designed to be flexible and self-expanding by using a knitting
structure that comprised poly-L-lactic acid (PLLA) with a
strut thickness of 225𝜇m and nitinol (Figure 1). By using a
dippingmethod, we loaded paclitaxel (PTX) to the PLLA/nit-
inol composite stent. Dip coating was performed by immers-
ing the PLLA/nitinol composite stent in a coating solution
(12% poly-lactide-co-glycolic acid [PLGA] + 2 : 3 v/v etha-
nol : dimethyl sulfoxide [DMSO]). For the purpose of achiev-
ing optimal PTX levels, we used multiple dipping methods.
By controlling the dipping time or contents of the solvent, we
regulated the PTX level loaded on a PLLA/nitinol composite
stent. The amount of PTX released by each sample was
measured by using high-performance liquid chromatogra-
phy (1% SDS in PBS, 37∘C). After analyzing variable PTX
loading methods, we chose to use two types of drug-
eluting PLLA/nitinol composite stents, a 50% (50 : 100, w/w)
PTX/PLGA (fast PTX-releasing form) hybrid stent, and a
30% (30 : 100, w/w) PTX/PLGA (slow PTX-releasing form)
hybrid stent.
2.2. Stent Implantation Procedure. This study was approved
by the Yonsei University Institutional Animal Care and Use
Committee. Experiments were planned by using 20 common
iliac arteries in 10 mini pigs. All the animals received 100mg
of aspirin and 300mg of clopidogrel at least 12 hours before
the procedure. All the animals received humane care in
compliance with the Animal Welfare Act and “The Guide
for the Care and Use of Laboratory Animals” formulated by
the Institute of Laboratory Animal Research [8]. Anesthesia
was induced by using intramuscular injections of ketamine
(20mg/kg) and xylazine (2mg/kg). After adequate systemic
anesthesia was attained, the animals were placed in the
supine position under mechanical ventilation and isoflurane
(1-2%) was delivered by using a precision vaporizer and circle
absorption breathing system, with periodic arterial blood gas
monitoring. After surgical exposure of the carotid artery,
an arteriotomy of the carotid artery was performed under
sterile conditions and a 6-Fr vascular access sheath was
inserted. During the procedure, vital signs were consistently
monitored by using surface electrocardiography. Prior to the
procedure, heparin (150 units/kg) was injected tomaintain an
activated clotting time of≥250 seconds. Based on quantitative
imaging analyses, oversized balloon inflation with a 1.3 : 1.0
balloon artery ratio was applied twice for a period of 30
seconds at a time in each iliac artery. After balloon injury,
four different types of stents were randomly implanted in
20 common iliac arteries under fluoroscopic guidance as
follows: a bare-metal stent (BMS; group 1, 𝑛 = 5), a drug-
free hybrid stent (group 2, 𝑛 = 5), a 50% PTX/PLGA (fast
PTX-releasing form) hybrid stent (group 3, 𝑛 = 5), and a 30%
PTX/PLGA (slow PTX-releasing form) hybrid stent (group
4, 𝑛 = 5). Operators were blinded to the types of stent used
for each procedure. After implantation, conventional angiog-
raphy was performed, and the carotid arteries were repaired
by using suture material suited until subsequent use of the
carotid arteries. All the animals received 100mg of aspirin
and 75mg of clopidogrel daily after stent implantation. The
animals were fed a regular diet throughout the duration of the
study. Follow-up angiography was performed, and gray-scale
intravascular ultrasonographic (IVUS) examinations were
conducted in the region of the inserted stent at 4 and 8 weeks
after stent implantation. A 2.9-Fr IVUS imaging catheter
(Eagle Eye, Volcano Corp, Rancho Cordova, CA) with a 20-
MHz phased-array transducer was used. Follow-up IVUS
imaging was not performed where angiography had shown
total in-stent occlusion. After 8 weeks, the animals were
euthanized and the iliac arteries were harvested.
2.3. Quantitative Coronary Angiography and Intravascular
Ultrasonographic Analysis. Quantitative angiography analy-
ses were performed by using an offline computerized quanti-
tative coronary angiographic system (CASS System, PieMed-
ical Imaging, Maastricht, The Netherlands) in an indepen-
dent core laboratory (Cardiovascular Research Center, Seoul,
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Table 1: Quantitative imaging analyses.
Group 1
(𝑛 = 5)
Group 2
(𝑛 = 5)
Group 3
(𝑛 = 5)
Group 4
(𝑛 = 5) 𝑝
Preprocedure RD (mm) 3.79 ± 0.50 4.20 ± 0.38 3.71 ± 0.52 4.00 ± 0.60 0.453
4-week follow-up
RD (mm) 3.72 ± 0.63 3.30 ± 1.09 3.63 ± 0.67 3.85 ± 0.82 0.778
MLD (mm) 3.01 ± 0.52 1.97 ± 0.81 2.11 ± 1.66 4.06 ± 0.39 0.013
DS (%) 19.0 ± 12.7 39.3 ± 18.1 46.8 ± 38.0 4.8 ± 4.2 0.032
8-week follow-up
RD (mm) 3.90 ± 0.39 3.39 ± 0.81 3.51 ± 0.54 4.02 ± 0.29 0.242
MLD (mm) 3.03 ± 0.46 1.80 ± 1.08 1.81 ± 1.67 3.39 ± 0.45 0.108
DS (%) 24.6 ± 4.8 47.3 ± 29.8 53.6 ± 42.5 14.6 ± 6.3 0.172
Group 1: bare-metal stent (BMS), group 2: drug-free hybrid stent, group 3: 50% PTX/PLGA (fast PTX-releasing form) hybrid stent, and group 4: 30%
PTX/PLGA (slow PTX-releasing form) hybrid stent.
RD: reference diameter, MLD: minimal luminal diameter, and DS: diameter stenosis.
Republic of Korea). The minimal lumen diameter (MLD)
with diameter stenosis and the reference diameter (RD) of the
treated iliac vessels were measured. The percentage of diam-
eter stenosis was calculated by using the following formula:
percent diameter = [(mean RD − MLD)/mean RD] × 100,
meanRD= (proximal reference vessel diameter + distal vessel
diameter)/2.
Conventional gray-scale quantitative IVUS analyses were
performed according to the criteria of the clinical expert
consensus document on IVUS and included the external
elastic membrane (EEM), lumen, plaque, and media (P&M;
P&M = EEM minus lumen) volumes [9]. Cross-sectional
IVUS images were analyzed at 1mm intervals. All IVUS
images were analyzed at the core laboratory (Cardiovascular
Research Center, Seoul, Republic of Korea) by analysts who
were blinded to the treatment and procedures performed in
each animal.
2.4. Histological Analysis. All the animals were euthanized
under anesthesia after the 8-week follow-up images had been
acquired. Immediately after the iliac arteries were harvested,
the stented vascular segments were fixed for 24 hours by
using 4% formaldehyde. After dehydration, the samples were
embedded in a glycol methacrylate (GMA) polymerization
solution (Technovit 7200VLC, Heraeus Kulzer Gmbh, Ger-
many). Each stented segment was cut proximally, medially,
and distally by using an EXAKT saw (EXAKT Apparatebau,
Germany); stained; dried; and glued onto EXAKT slides; and
polished down by using an EXAKT-polish machine (EXAKT
400 CS, EXAKT Apparatebau, Germany). Data analysis was
performed by using a microscope (GE-OEC Series 9800,
USA) and its corresponding imaging software (Sigmascan
Pro, Systat Software Inc., USA). All embedded sections were
stained with hematoxylin-eosin.
2.5. Evaluation of Inflammatory and Vessel Injury Scores.
Inflammatory scores were defined as follows: 0, no inflam-
matory cells surrounding the strut; 1, light, noncircum-
ferential lymphohistiocytic infiltrate surrounding the strut;
2, localized, noncircumferential, moderate-to-dense cellular
aggregate surrounding the strut; and 3, circumferential dense
lymphohistiocytic cell infiltration of the strut [10, 11]. The
vessel injury score was graded as follows: 0, internal elastic
lamina intact; 1, internal elastic lamina lacerated; 2, internal
elastic lacerated; and 3, external elastic lamina lacerated [10].
2.6. Statistical Analysis. Statistical analysis was performed by
using SPSS (Version 20.0.0, IBM, Armonk, NY, USA). Data
were expressed as number (%) or mean ± standard devia-
tion or median (interquartile range). Continuous variables
were compared by using one-way analysis of variance or
the Kruskal-Wallis test. Abnormally distributed continuous
variables were compared by using theMann–Whitney𝑈 test.
Comparisons of categorical data were performed by using
chi-square or Fisher exact test. A Pearson correlation analysis
was performed to evaluate the correlation between changes
in MLD. A 𝑝 value of <0.05 was considered statistically
significant.
3. Results and Discussion
3.1. Results. All the stents were successfully implanted to both
common iliac arteries in all the 10 animals.The findings from
the quantitative imaging analyses are presented inTable 1.The
RDs of the iliac arteries before the procedure, at the 4-week
follow-up, or at the 8-week follow-up did not show significant
differences. When groups 1, 2, 3, and 4 were compared, group
4 showed less diameter stenosis in the 30% PTX/PLGA (slow
PTX-releasing form) hybrid stent at the 4-week follow-up
(19.0% ± 12.7% versus 39.3% ± 18.1% versus 46.8% ± 38.0%
versus 4.8% ± 4.2%, resp.; 𝑝 = 0.032, Figure 2). The MLD
in group 4 (3.39 ± 0.45mm) also tended to be greater than
that in the other groups at the 8-week follow-up, although
the difference was not statistically significant (𝑝 = 0.108).
However, the MLD in group 4 showed more favorable results
when compared with those in groups 2 (drug-free hybrid
stent) and 3 (50% PTX/PLGA, fast PTX-releasing hybrid
stent; Figure 3).
The findings from the IVUS imaging analyses are sum-
marized in Table 2. IVUS imaging was not performed if
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Table 2: Intravascular ultrasonographic findings from the maximum neointimal site at 4- and 8-week follow-ups.
Group 1
(𝑛 = 5)
Group 2
(𝑛 = 5)
Group 3
(𝑛 = 4)
Group 4
(𝑛 = 5) 𝑝
4-week follow-up
Stent area, mm2 23.0 ± 1.1 20.8 ± 2.7 22.6 ± 5.0 24.9 ± 2.5 0.218
Lumen area, mm2 12.9 ± 6.4 8.4 ± 3.3 10.2 ± 5.2 18.2 ± 4.3 0.037
Neointimal area, mm2 10.0 ± 5.8 12.4 ± 3.3 12.6 ± 4.7 6.8 ± 3.7 0.196
Percentage of NIH (%) 44.3 ± 25.9 59.8 ± 14.7 56.1 ± 17.4 27.4 ± 15.3 0.072
8-week follow-up (𝑛 = 5) (𝑛 = 4) (𝑛 = 3) (𝑛 = 5)
Stent area, mm2 23.1 ± 1.3 19.2 ± 3.4 23.6 ± 6.1 23.6 ± 3.1 0.248
Lumen area, mm2 9.5 ± 2.7 7.5 ± 3.7 12.5 ± 3.9 12.9 ± 2.2 0.072
Neointimal area, mm2 13.6 ± 1.9 11.7 ± 1.6 11.2 ± 2.6 10.7 ± 3.8 0.379
Percentage of NIH (%) 59.1 ± 10.4 62.6 ± 14.8 47.5 ± 4.9 44.5 ± 12.0 0.104
Group 1: bare-metal stent (BMS), group 2: drug-free hybrid stent, group 3: 50% PTX/PLGA (fast PTX-releasing form) hybrid stent, and group 4: 30%
PTX/PLGA (slow PTX-releasing form) hybrid stent.
NIH: neointimal hyperplasia.
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Figure 2: Comparison of diameter stenosis among the groups (∗𝑝 < 0.05). (a) At 4-week follow-up. (b) At 8-week follow-up. G1 (group 1):
bare-metal stent (BMS), G2 (group 2): drug-free hybrid stent, G3 (group 3): 50% PTX/PLGA (fast PTX-releasing form) hybrid stent, and G4
(group 4): 30% PTX/PLGA (slow PTX-releasing form) hybrid stent.
angiography showed total in-stent occlusion. One lesion in
group 3 showed total occlusion at the 4-week follow-up,
while one lesion in group 2 and two lesions in group 3
showed total occlusion at the 8-week follow-up. IVUS images
obtained at the 4-week follow-up showed that the lumen
area in group 4 was significantly larger than that in the
other groups. The neointimal area of the group 4 stent also
tended to be less than that of the other stents used, although
the difference was not statistically significant. IVUS images
obtained at the 8-week follow-up showed similar results,
although no statistically significant differences were observed
in the lumen and neointimal area.The stent area as measured
by using IVUS did not show statistically significant changes
during the study periods across the groups.
The findings from the histopathological assessment are
presented in Table 3. All group 1 (𝑛 = 5) and group 4 (𝑛 = 5)
stents showed a low-grade inflammatory score (0-1) 8 weeks
after stent implantation. Furthermore, all the group 4 stents
showed a low-grade vessel injury score (0-1) at 8 weeks after
the procedure. Figure 4 shows representative histological
images of each stent type.
3.2. Discussion. The major findings of this study were as
follows: (1) our newhybrid biodegradable stent designed to be
self-expanding with a knitting structure composed of PLLA
and nitinol was easy to deploy without complication and (2)
the 30% PTX/PLGA (slow PTX-releasing form) hybrid stent
more effectively inhibited neointimal hyperplasia without
inflammation and vascular injury compared to the other stent
types.
Self-expandable nitinol stents have been developed for
the treatment of femoropopliteal disease, and primary nitinol
stenting is recommended as a first-line treatment for superfi-
cial femoral artery lesions [3, 4, 12]. However, the high rate
BioMed Research International 5
Table 3: Histopathological assessment of porcine iliac arteries 8 weeks after stenting.
Group 1
(𝑛 = 5)
Group 2
(𝑛 = 5)
Group 3
(𝑛 = 5)
Group 4
(𝑛 = 5) 𝑝
Inflammatory score, n (%) 0.172
0-1 5 (100) 3 (60) 3 (60) 5 (100)
2-3 0 (0) 2 (40) 2 (40) 0 (0)
Vessel injury score, n (%) 0.414
0-1 3 (60) 3 (60) 3 (60) 5 (100)
2-3 2 (40) 2 (40) 2 (40) 0 (0)
Group 1: bare-metal stent (BMS), group 2: drug-free hybrid stent, group 3: 50% PTX/PLGA (fast PTX-releasing form) hybrid stent, and group 4: 30%
PTX/PLGA (slow PTX-releasing form) hybrid stent.
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Figure 3: Serial changes in minimal luminal diameter at 4- and
8-week follow-ups (∗𝑝 < 0.05). G1 (group 1): bare-metal stent
(BMS), G2 (group 2): drug-free hybrid stent, G3 (group 3): 50%
PTX/PLGA (fast PTX-releasing form) hybrid stent, and G4 (group
4): 30% PTX/PLGA (slow PTX-releasing form) hybrid stent.
of in-stent restenosis is a major problem of endovascular
treatment with metallic stents [13]. Furthermore, previous
case reports have shown that nitinol stents have major
limitations attributable to their metallic components, such
as stent fracture or crushed stents [14, 15]. Biodegradable
scaffolds have clear advantages over metallic stents, not only
for coronary intervention but also for peripheral artery revas-
cularization, including lower incidence of adverse events such
as thrombotic stent reocclusion and stent fracture [16, 17].
PLLA consists of a crystalline component of semicrystalline
polymer and is widely used in biodegradable scaffolds [16, 18].
In general, in vivo studies that investigated bioresorbable
scaffolds have shown an initial reduction inmolecularweight,
a decrease in radial support at about 6 months, loss in
mass starting at 12 months, and subsequent completion at
24 months [16, 18, 19]. However, radial support for just 6
months may not be sufficient for peripheral artery interven-
tion, considering that these arteries encounter a significant
amount of compression, torsion, extension, and bending. In
the present study, IVUS findings demonstrated that our new
biodegradable stent did not show significant recoil during the
8-week follow-up period. This new biodegradable stent for
the treatment of PAD is expected to provide superior radial
support when compared with conventional bioresorbable
scaffolds consisting only of PLLA.
Several recent studies have suggested that clinical out-
comes in patients treated with everolimus-eluting biore-
sorbable scaffolds for coronary artery revascularization are
within the range for noninferiority when compared with
drug-eluting metallic stents [20–23]. Werner et al. previously
reported their experience with the use of a biodegradable
balloon expandable stent composed of PLLA, the Igaki-Tamai
biodegradable stent, for the treatment of de novo lesions in
the femoral artery [6]. The authors demonstrated excellent
short-term results; however, sustainable luminal patency over
time and inflammatory reaction continue to be concerns.
That bioabsorbable polymer is more likely to be associated
with an inflammatory reaction compared to a nitinol-based
BMS. The results of the present study found that the 30%
PTX/PLGA (slow PTX-releasing form) hybrid stent showed
a low level of inflammation comparable with that with BMS.
Therefore, our new hybrid biodegradable drug-eluting stent
for the treatment of PAD has potential clinical benefits by
reducing the inflammatory reaction after stent implantation.
Furthermore, we expect that our new hybrid biodegradable
stent will enable vascular surgeons to easily perform surgical
procedures for stenting lesions after stent restenosis.
The present study demonstrated that the 30% PTX/PLGA
(slow PTX-releasing form) hybrid stent in group 4 was more
strongly associated with inhibition of in-stent neointimal
hyperplasia than the drug-free hybrid stent (group 2) and
the 50% PTX/PLGA (fast PTX-releasing form) hybrid stent
(group 3). A study that evaluated the kinetics of paclitaxel
release on the neointima showed that the longer-releasing
paclitaxel-eluting stent had the best results in terms of inhibi-
tion of in-stent neointimal hyperplasia [24]. Our findings also
suggest that the duration of paclitaxel release had a significant
impact on the suppression of in-stent neointimal hyperplasia.
While clear reasons for these results are uncertain, we
hypothesized that the inhibition of the proliferative reaction
requires a minimum period.
This study had several limitations. First, this studywas not
based on the atherosclerotic porcine peripheral arterymodel.
Therefore, its results require cautionwhen applied in a clinical
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Figure 4: Representative histological images of each stent. (a) A bare-metal stent (group 1). (b) A drug-free hybrid stent (group 2). (c) A 50%
PTX/PLGA (fast PTX-releasing form) hybrid stent (group 3). (d) A 30% PTX/PLGA (slow PTX-releasing form) hybrid stent (group 4).
setting for the treatment of atherosclerotic PAD. Second, the
statistical power of our findings was not sufficient because
of the relatively small sample size and short study period.
However, angiography results were statistically significant at
the 4-week follow-up and IVUS findings were similar to the
quantitative imaging analysis results. Third, we did not fully
evaluate the total occluded stent segments by using IVUS.
However, we analyzed all histopathological assessment results
regardless of total occlusion.
4. Conclusion
Our new self-expandable, biodegradable 30% PTX/PLGA
(slow-releasing form) stent was successfully implanted to
all iliac arteries and showed the most favorable results for
patency and safety when comparedwith the other stent types.
These findings strongly suggest the need for further, large-
scale, and long-term experimental study aimed at clinical
application. However, our study provides new concepts for
developing a new biodegradable stent for the treatment of
PAD.
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